Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 408

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Use of renin–angiotensin–aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study

Open access
de Abajo, Francisco J, Rodríguez-Martín, Sara, Lerma, Victoria, Mejía-Abril, Gina, Aguilar, Mónica, García-Luque, Amelia, Laredo, Leonor, Laosa, Olga, Centeno-Soto, Gustavo A, Ángeles Gálvez, Maria, Puerro, Miguel, González-Rojano, Esperanza, Pedraza, Laura, de Pablo, Itziar, Abad-Santos, Francisco, Rodríguez-Mañas, Leocadio, Gil, Miguel, Tobías, Aurelio, Rodríguez-Miguel, Antonio, Rodríguez-Puyol, Diego, Barreira-Hernandez, D, Zubiaur, P, Santos-Molina, E, Pintos-Sánchez, E, Navares-Gómez, M, Aparicio, R M, García-Rosado, V, Gutiérrez-Ortega, C, Pérez, C, Ascaso, A, Elvira, C·2020·The Lancet

Abstract

Summary Background Concerns have been raised about the possibility that inhibitors of the renin–angiotensin–aldosterone system (RAAS) could predispose individuals to severe COVID-19; however, epidemiological evidence is lacking. We report the results of a case-population study done in Madrid, Spain, since the outbreak of COVID-19. Methods In this case-population study, we consecutively selected patients aged 18 years or older with a PCR-confirmed diagnosis of COVID-19 requiring admission to hospital from seven hospitals in Madrid, who had been admitted between March 1 and March 24, 2020. As a reference group, we randomly sampled ten patients per case, individually matched for age, sex, region (ie, Madrid), and date of admission to hospital (month and day; index date), from Base de datos para la Investigación Farmacoepidemiológica en Atención Primaria (BIFAP), a Spanish primary health-care database, in its last available year (2018). We extracted information on comorbidities and prescriptions up to the month before index date (ie, current use) from electronic clinical records of both cases and controls. The outcome of interest was admission to hospital of patients with COVID-19. To minimise confounding by indication, the main analysis focused on assessing the association between COVID-19 requiring admission to hospital and use of RAAS inhibitors compared with use of other antihypertensive drugs. We calculated odds ratios (ORs) and 95% CIs, adjusted for age, sex, and cardiovascular comorbidities and risk factors, using conditional logistic regression. The protocol of the study was registered in the EU electronic Register of Post-Authorisation Studies, EUPAS34437. Findings We collected data for 1139 cases and 11 390 population controls. Among cases, 444 (39·0%) were female and the mean age was 69·1 years (SD 15·4), and despite being matched on sex and age, a significantly higher proportion of cases had pre-existing cardiovascular disease (OR 1·98, 95% CI 1·62–2·41) and risk factors (1·46, 1·23–1·73) than did controls. Compared with users of other antihypertensive drugs, users of RAAS inhibitors had an adjusted OR for COVID-19 requiring admission to hospital of 0·94 (95% CI 0·77–1·15). No increased risk was observed with either angiotensin-converting enzyme inhibitors (adjusted OR 0·80, 0·64–1·00) or angiotensin-receptor blockers (1·10, 0·88–1·37). Sex, age, and background cardiovascular risk did not modify the adjusted OR between use of RAAS inhibitors and COVID-19 requiring admission to hospital, whereas a decreased risk of COVID-19 requiring admission to hospital was found among patients with diabetes who were users of RAAS inhibitors (adjusted OR 0·53, 95% CI 0·34–0·80). The adjusted ORs were similar across severity degrees of COVID-19. Interpretation RAAS inhibitors do not increase the risk of COVID-19 requiring admission to hospital, including fatal cases and those admitted to intensive care units, and should not be discontinued to prevent a severe case of COVID-19. Funding Instituto de Salud Carlos III.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(20)31030-8

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 32 references

Cited by

See all 408

Metadata

Authors
de Abajo, F. J., Rodríguez-Martín, S., Lerma, V., Mejía-Abril, G., Aguilar, M., García-Luque, A., Laredo, L., Laosa, O., Centeno-Soto, G. A., Ángeles Gálvez, M., Puerro, M., González-Rojano, E., Pedraza, L., de Pablo, I., Abad-Santos, F., Rodríguez-Mañas, L., Gil, M., Tobías, A., Rodríguez-Miguel, A., Rodríguez-Puyol, D., Barreira-Hernandez, D., Zubiaur, P., Santos-Molina, E., Pintos-Sánchez, E., Navares-Gómez, M., Aparicio, R. M., García-Rosado, V, Gutiérrez-Ortega, C., Pérez, C., Ascaso, A., & Elvira, C.
Venue
The Lancet
Publisher
Elsevier BV
Published
2020-05
Volume
395
Issue
10238
Pages
1705-1714
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W3025099648
Cited by
408
References
32
FWCI
11.71
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Use of renin–angiotensin–aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study. https://app.cochat.ai/papers/10.1016/s0140-6736(20)31030-8
The paper
de Abajo, F. J., Rodríguez-Martín, S., Lerma, V., Mejía-Abril, G., Aguilar, M., García-Luque, A., Laredo, L., Laosa, O., Centeno-Soto, G. A., Ángeles Gálvez, M., Puerro, M., González-Rojano, E., Pedraza, L., de Pablo, I., Abad-Santos, F., Rodríguez-Mañas, L., Gil, M., Tobías, A., Rodríguez-Miguel, A., . . . Elvira, C. (2020). Use of renin–angiotensin–aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study. The Lancet. https://doi.org/10.1016/s0140-6736(20)31030-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.